Divis Labs’ revenue for the quarter amounted to Rs. 2,238 crore, marking a 17% y-o-y increase and a 6% q-o-q rise, which was 4% above estimates. EBITDA stood at Rs. 616 crore, reflecting a 29% y-o-y increase but a slight decline of 1% q-o-q, falling short of our expectations by 4%. Margins stood at 28%, indicating a 243 bps y-o-y improvement but a 184 bps q-o-q decrease. PAT reached Rs. 510 crore, showing a 47% increase y-o-y and a 19% q-o-q rise, exceeding our estimates by 15%.
OutlookWe observe a consistent increase across all key financial metrics, indicating a significant potential for stock. Therefore, we maintain BUY. Currently, at the CMP, the stock is priced at 70x the FY2026E EPS of Rs. 83.89 and 59x the FY2027E EPS of Rs. 100.30. Given the sustained growth in the custom synthesis business, we have established a PT of Rs. 6,812.
For all recommendations report, click hereDisclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Divis Laboratories_12112024_SharekhanDiscover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
